Private Capital Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Private Capital Advisors’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,000	Closed	-$551K	–	96
2018 Q1	$551K	Sell	10,000 -29,397	-75%	-$1.76M	0.18%	68
2017 Q4	$2.21M	Buy	39,397 +29,401	+294%	+$1.66M	0.77%	37
2017 Q3	$612K	Sell	9,996 -10,004	-50%	-$569K	0.21%	72
2017 Q2	$1.07M	Sell	20,000 -20,372	-50%	-$994K	0.35%	64
2017 Q1	$1.95M	Buy	+40,372	New	+$1.88M	0.64%	44
2016 Q4	–	Sell	-17,140	Closed	-$831K	–	119
2016 Q3	$831K	Buy	+17,140	New	+$814K	0.3%	65

Other funds holding BIB

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BKS Advisors Southfield, Michigan $249M AUM 25.49% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

SAM

Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return

BRC

Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return

Private Capital Advisors's BIB Position: Q2 2018 in Review

Private Capital Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2018, closing a stake of 10,000 shares — an estimated $551K sold.

Private Capital Advisors first reported a position in BIB in Q3 2016 and held it in 6 quarters. The position peaked at $2.21M in Q4 2017. 38 funds tracked by Wall St. Rank hold BIB as of Q2 2018.

Private Capital Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2018 after selling out during the quarter.
Private Capital Advisors sold 10,000 ProShares Ultra NASDAQ Biotechnology shares in Q2 2018, an estimated $551K.
Private Capital Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2016 and held it in 6 quarters.
Private Capital Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $2.21M in Q4 2017.
38 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2018.

Based on Private Capital Advisors's 13F filing for Q2 2018, filed 10 Jul 2018.